/PEAR
PEAR Stock - Pear Therapeutics, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$0.03+0.00%
+$0.00 (+0.00%) • Apr 18
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.99
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+22160.3%upside
Target: $6.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PEAR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.03 – $0.03
TARGET (TP)$6.50
STOP LOSS$0.03
RISK/REWARD1:-8088.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.52
52W High$6.74
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $12.69M | $4.21M | $9.38M | $32.56M |
| Gross Profit | $4.51M | $-1,025,000 | $7.67M | $31.56M |
| Gross Margin | 35.5% | -24.4% | 81.7% | 96.9% |
| Operating Income | $-123,350,000 | $-105,685,000 | $-76,644,000 | $-31,603,000 |
| Net Income | $-23,740,000 | $-20,294,000 | $-100,583,000 | $12.39M |
| Net Margin | -187.0% | -482.3% | -1071.9% | 38.1% |
| EPS | $-0.17 | $-0.18 | $-0.73 | $0.09 |
Company Overview
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PEARBeat Rate
40%
Last 5 quarters
Avg Surprise
+37.8%
EPS vs Estimate
Beats / Misses
2/3
Last 12 quarters
Latest EPS
$0.21
Q1 2023
EPS Surprise History
Q1 21
No data
Q2 21
No data
Q3 21
No data
Q1 22
-4.3%
$-0.24vs$-0.23
Q2 22
-8.3%
$-0.26vs$-0.24
Q3 22
+12.0%
$-0.22vs$-0.25
Q4 22
-4.8%
$-0.22vs$-0.21
Q1 23
+194.5%
$0.21vs$-0.22
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Mar 29, 2024 | — | — | — | — |
Q4 2023 | Nov 13, 2023 | — | — | — | — |
Q3 2023 | Aug 9, 2023 | $-0.16 | — | — | — |
Q2 2023 | May 15, 2023 | $0.14 | — | — | — |
Q1 2023 | Mar 31, 2023 | $-0.22 | $0.21 | +194.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.21 | $-0.22 | -4.8% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.25 | $-0.22 | +12.0% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.23 | $-0.24 | -4.3% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | — | $0.84 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.34 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.29 | — | — |
Latest News
Loading news...
Frequently Asked Questions about PEAR
What is PEAR's current stock price?
Pear Therapeutics, Inc. (PEAR) is currently trading at $0.03 per share. The stock has moved +0.00% today.
What is the analyst price target for PEAR?
The average analyst price target for PEAR is $6.50, based on 1 analyst.
What sector is Pear Therapeutics, Inc. in?
Pear Therapeutics, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is PEAR's market cap?
Pear Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PEAR pay dividends?
No, Pear Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPTO
Aptose Biosciences Inc.
$1.71
Mkt Cap: $0.0B
GMDA
Gamida Cell Ltd.
$0.03
Mkt Cap: $0.0B
GRTS
Gritstone bio, Inc.
$0.03
Mkt Cap: $0.0B
HILS
Hillstream BioPharma, Inc.
$0.24
Mkt Cap: $0.0B
MDGS
Xylo Technologies Ltd.
$2.36
Mkt Cap: $0.0B
NBRVF
Nabriva Therapeutics plc
$0.00
Mkt Cap: $0.0B
RMED
Ra Medical Systems, Inc.
$0.59
Mkt Cap: $0.0B
TNFA
TNF Pharmaceuticals, Inc.
$5.20
Mkt Cap: $0.0B
UPH
UpHealth, Inc.
$0.30
Mkt Cap: $0.0B
VRAY
ViewRay, Inc.
$0.03
Mkt Cap: $0.0B
Explore stocks similar to PEAR for comparison